[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601905":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":37,"centralContacts":41,"locations":47,"responsibleParty":64,"collaborators":23,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":23,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":23,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":23,"overallStatus":86,"whyStopped":23,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Jinan Central Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental Arm","EXPERIMENTAL","Palliative radiotherapy combined with iparomlimab and tuvonralimab (QL1706), trifluridine\u002Ftipiracil (TAS-102), and bevacizumab.",[13,14,15,16],"Radiation: Palliative radiotherapy","Drug: Iparomlimab and tuvonralimab","Drug: TAS-102","Drug: Bevacizumab",[18,24,29,33],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"RADIATION","Palliative radiotherapy","Conventional fractionation, low-dose hypofractionated radiotherapy, or high-dose hypofractionated radiotherapy may be employed.",[9],null,{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":23},"DRUG","Iparomlimab and tuvonralimab","5 mg\u002Fkg, intravenously infused on Day 1 of each cycle, administered every 3 weeks (with each cycle defined as 21 days).",[9],{"type":25,"name":30,"description":31,"armGroupLabels":32,"otherNames":23},"TAS-102","35 mg\u002Fm², orally twice daily on Days 1 to 5 and Days 8 to 12 of each cycle, with each cycle spanning 28 days (4 weeks).",[9],{"type":25,"name":34,"description":35,"armGroupLabels":36,"otherNames":23},"Bevacizumab","7.5 mg\u002Fkg via intravenous infusion on Day 1 of each 21-day cycle.",[9],[38],{"name":39,"affiliation":5,"role":40},"Meili Sun, Director, Department of Oncology, MD, PhD,","PRINCIPAL_INVESTIGATOR",[42],{"name":43,"role":44,"phone":45,"phoneExt":23,"email":46},"Yawen Zhen, Associate Director, Department of Oncology","CONTACT","+86 150 2001 0760","my123454321@126.com",[48],{"facility":5,"status":23,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Jinan","Shandong","250000","China","CN",{"type":55,"coordinates":56},"Point",[57,58],116.99722,36.66833,{"lat":58,"lon":57},[61,62],{"name":43,"role":44,"phone":45,"phoneExt":23,"email":46},{"name":63,"role":40,"phone":23,"phoneExt":23,"email":23},"Meili Sun, Director, Department of Oncology, MD, PhD",{"type":40,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"Meili Sun","Director of Department of Oncology","100601905","phase-2-radiotherapy-combined-ql1706-tas-102-and-bevacizumab-in-mcrc-100601905",false,"NCT07116577","Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC","A Single-Arm, Exploratory Study of Palliative Radiotherapy Combined With Iparomlimab and Tuvonralimab, Trifluridine\u002FTipiracil (TAS-102), and Bevacizumab in Later-Line Treatment of Advanced Colorectal Cancer","Inclusion Criteria:\n\n* Aged 18 to 75 years .\n* Histologically confirmed unresectable colorectal adenocarcinoma.\n* Patients must have received at least one prior line of oxaliplatin-, irinotecan-, or 5-FU-based therapy with documented progression or intolerance.\n* Documented KRAS and BRAF mutation status (mutant or wild-type) must be available.\n* Palliative radiotherapy targeting primary or metastatic lesions is planned.\n* At least one measurable lesion per RECIST v1.1 exists.\n* ECOG score of 0-1 and life expectancy ≥12 weeks.\n* Adequate bone marrow, hepatic, and renal function must be demonstrated.\n* Fertile patients commit to using effective contraception during and for 6 months post-treatment.\n\nExclusion Criteria:\n\n* History of Grade ≥3 immune-related adverse events (irAEs) from prior immunotherapy deemed contraindications for retreatment.\n* Radiation or systemic anticancer therapy within 14 days prior to first study treatment.\n* Active CNS metastases and\u002For leptomeningeal disease (LMD). Symptomatic interstitial lung disease (ILD), active pneumonitis, uncontrolled infections, or non-healing wounds\u002Ffistulae.\n* Intestinal perforation risks: active diverticulitis, intra-abdominal abscess, GI obstruction, or cancer-related peritoneal carcinomatosis.\n* Uncontrolled or symptomatic serous cavity effusions (pleural, ascites, pericardial).\n* Uncontrolled cardiovascular\u002Fcerebrovascular diseases.\n* Medical\u002Fsocial conditions that may compromise study results or lead to premature termination per investigator judgment.","ALL","18 Years","75 Years",{"count":78,"type":79},37,"ESTIMATED","INTERVENTIONAL",[82],"PHASE2","This single-center, single-arm, prospective study plans to enroll patients with advanced colorectal cancer who have failed first-line or higher systemic therapies. Participants will receive a combination of iparomlimab and tuvonralimab (QL1706), trifluridine\u002Ftipiracil (TAS-102), bevacizumab, and palliative radiotherapy. The efficacy and safety of this combination therapy will be evaluated by assessing objective response rate (ORR), progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety profile.",[85],"mCRC","NOT_YET_RECRUITING","2025-08-06",{"date":89,"type":90},"2025-08-11","ACTUAL",{"date":92,"type":79},"2025-08-31",{"date":94,"type":79},"2028-12-31",{"name":5,"class":6},1]